As organizations representing patients with serious, life-threatening, chronic, complex and disabling conditions, we have serious concerns regarding the adverse impact that out-of-pocket (OOP) costs have on patient access and adherence to medically necessary treatment.
Cost-sharing has far-reaching implications concerning the connection between access and health because delayed initiation of treatment or inability to remain on treatment due to OOP costs worsens health outcomes. Cost-sharing creates a two-class system with respect to prescription medications: patients with adequate resources can access the full spectrum of health benefits from innovative advances in biotechnology and drug development while those with insufficient resources may have to settle for less-expensive treatments that may be less effective than newer options; skip doses; skip a refill; or forgo the medications altogether. Our organizations feel strongly that OOP costs should not prevent people from accessing the medications they need and remaining on treatment as long as their providers indicate is required.
Was this helpful?